drugset / Trial / NCT02052219
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.
Timeline
- Start
- 2014-10
- Primary completion
- 2016-10
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blisibimod | Peptide | — | Subcutaneous |